Neuroprotective actions of selegiline
Open accessThe DOI matches its Crossref record.
Abstract
Selegiline, a selective inhibitor of monoamine oxidase‐B (MAO‐B), was one of the first adjunct therapies in clinical neurology. A retrospective analysis of data from patients with Parkinson's disease found a significant increase in survival in those treated with selegiline plus L‐dopa compared with L‐dopa alone. The mechanism of action of selegiline is complex and cannot be explained solely by its MAO‐B inhibitory action. Pretreatment with selegiline can protect neurons against a variety of neurotoxins, such as 1‐methyl‐4‐phenyl‐1,2,3,6 tetrahydropyridine (MPTP), 6‐hydroxydopamine, N‐(2‐chloroethyl)‐N‐ethyl‐2‐bromobenzylamine (DSP‐4), methyl‐β‐acetoxyethyl‐2‐chloroethylamine (AF64A), and 5,6‐dihydroxyserotonin, which damage dopaminergic, adrenergic, cholinergic, and sertoninergic neurons, respectively. Selegiline produces an amphetamine‐like effect, enhances the release of dopamine, and blocks the reuptake of dopamine. It stimulates gene expression of L‐aromatic amino acid decarboxylase, increases striatal phenylethylamine levels, and activates dopamine receptors. Selegiline reduces the production of oxidative radicals, up‐regulates superoxide dismutase and catalase, and suppresses nonenzymatic and iron‐catalyzed autooxidation of dopamine. Selegiline compensates for loss of target‐derived trophic support, delays apoptosis in serum‐deprived cells, and blocks apoptosis‐related fall in the mitochondrial membrane potential. Most of the aforementioned properties occur independently of selegiline's efficacy to inhibit MAO‐B. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
“…(MPTP), 6-hydroxydopa- mine, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), methyl-beta-acetoxyethyl-2-chloroethylamine (AF64A), and 5,6- dihydroxyserotonin, which damage dopaminergic, adrenergic, cholinergic, and sertoninergic neurons, respectively (Ebadi et al., 2002).”
Selegiline slows the progression of the symptoms of Parkinson disease
Pålhagen, S., Heinonen, E., Hägglund, J., Kaugesaar, T., Mäki-Ikola, O., Palm, R., & the Swedish Parkinson Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000204007.46190.54 · Cited by 271
Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
Hare, D. J., Adlard, P. A., Doble, P. A., & Finkelstein, D. I. (2013) · Metallomics · doi:10.1039/c2mt20164j · Cited by 78
Small-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Metadata
- Authors
- Ebadi, M., Sharma, S., Shavali, S., & El Refaey, H.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2002-01-07
- Volume
- 67
- Issue
- 3
- Pages
- 285-289
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2080496794
- Cited by
- 132
- References
- 0
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.